Find information on thousands of medical conditions and prescription drugs.

Kytril

Granisetron is a serotonin 5-HT₃ receptor antagonist used to treat nausea and vomiting following chemotherapy. Its main affect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. more...

Home

Diseases

Medicines

Clonazepam

K-Dur

Kadian

Kainic acid

Kanamycin

Kantrex

Kariva

Kayexalate

Keflex

Kefzol

Kemstro

Keppra

Ketalar

Ketek

Kionex

Klotrix

Konazol

Korostatin

Kytril

Granisetron was invented by chemists working at the British drug company Beecham around 1988 and is expected to go generic in 2007/2008. It is produced by Roche Laboratories under the trade name Kytril®. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA.

Granisetron breaks down slowly, staying in the body for a long time. One dose usually lasts 4 to 9 hours and is usually administered once or twice daily. This drug is removed from the body by the liver and kidneys.

Clinical Uses

Chemotherapy-induced nausea and vomiting
- 5-HT₃ receptor antagonists are the primary drugs used to treat and prevent chemotherapy-induced nausea and vomiting. Many times they are given intravenously about 30 minutes before beginning therapy.
Post-operative and post-radiation nausea and vomiting
Is a possible therapy for nausea and vomiting due to acute or chronic medical illness or acute gastroenteritis
Treatment of Cyclic vomiting syndrome although there are no formal trials to confirm efficacy.

Adverse Effects

Granisetron is a well-tolerated drug with few side effects. Headache, dizziness, and constipations are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the liver's cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

Read more at Wikipedia.org

• [List your site here Free!]

Innovatix Announces New Contract with Roche Pharmaceuticals; Kytril Now Available for Long Term Care Members
From Business Wire, 1/30/02

Business Editors and Medical/Health Writers

NEW YORK--(BW HealthWire)--Jan. 30, 2002

Innovatix, one of the fastest growing group purchasing organizations in the alternate site marketplace, announced the roll-out of a special pricing program with Roche Pharmaceuticals for the drug Kytril, for Innovatix's long term care providers.

Kytril is an anti-emetic drug indicated for the prevention of nausea and vomiting associated with chemotherapy and radiation.

"This contract provides our long term care pharmacy members with extremely competitive pricing on a drug that was not previously offered to them through group purchasing programs. The Innovatix long term care members will be especially pleased with this outstanding savings program for Kytril," explained John P. Sganga, President and CEO of Innovatix.

Established in 1993, Innovatix is a division of GNYHA Ventures, Inc., a wholly owned, for-profit subsidiary of the Greater New York Hospital Association (GNYHA). Innovatix offers alternate care providers cost savings through group purchasing contracts with pharmaceutical, medical/surgical, and office supply manufacturers. Innovatix's over 2,700 members include home infusion providers, independent medical oncologists, long-term care facilities, and ambulatory surgery centers. Innovatix can be reached toll-free at 888-258-3273, or on the Web at www.innovatix.com.

About Roche Pharmaceuticals

Hoffman-LaRoche, Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche discovers, develops, manufactures and markets numerous important prescription drugs that enhance people's health, well-being and quality of life. Among the company's areas of therapeutic interest are: dermatology; genitourinary disease; infectious diseases, including influenza; inflammation, including arthritis and osteoporosis; metabolic diseases, including obesity and diabetes; neurology; oncology; transplantation; vascular diseases; and virology, including HIV/AIDS and hepatitis C.

For more information on the Roche pharmaceuticals business in the United States, visit the company's Web site at: http://www.rocheusa.com

Return to Kytril

Home

Contact

Resources

Exchange Links

ebay